Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sara Negrotto

Interventional Cardiology Knoxville, TN Medical Doctor

NPI 1932456621 CMS profile 1309655

9320 Park West Blvd, Knoxville, TN 37923

Open in the dashboard

General payments

$113,664

756 records reported · program years 2019–2025

Research payments

$4,559

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Negrotto of Knoxville, TN is reported in the CMS Open Payments database as having received $113,664 across 756 general payments and $4,559 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,400 86
2024 General $30,793 131
2023 General $52,130 313
2023 Research $4,559 2
2022 General $5,368 135
2021 General $2,486 61
2020 General $1,930 23
2019 General $557 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Negrotto
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sara Negrotto were reported at $20,400. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sara Negrotto Interventional Cardiology median Middle half National median
2019 $557 $1,097 $329–$3,048 $163
2020 $1,930 $473 $161–$1,480 $114
2021 $2,486 $677 $233–$1,827 $132
2022 $5,368 $978 $333–$2,724 $149
2023 $52,130 $1,136 $382–$2,986 $160
2024 $30,793 $1,181 $395–$3,326 $164
2025 $20,400 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $91,089 448 payments
  2. Medtronic, Inc. $7,640 81 payments
  3. Edwards Lifesciences Corporation $6,172 74 payments
  4. Abbott Laboratories $4,271 54 payments
  5. Boston Scientific Corporation $1,645 55 payments
  6. Medtronic Vascular, Inc. $1,089 16 payments
  7. AngioDynamics, Inc. $824 11 payments
  8. Shockwave Medical, Inc $375 5 payments
  9. Cardiovascular Systems Inc. $196 2 payments
  10. Atricure, Inc. $103 1 payment
  11. Other $260 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $59,350 10 payments
  2. Food and Beverage $19,804 698 payments
  3. Travel and Lodging $18,406 40 payments
  4. Consulting Fee $10,405 3 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,656 3 payments
  6. Education $43 2 payments
Products named General payments · program years 2019–2025
  1. Impella $73,250 395 payments
  2. COREVALVE EVOLUT R $6,594 44 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $2,312 15 payments
  4. CoreValve Evolut Transcatheter Valve Systems $1,089 16 payments
  5. CoreValve Evolut Transcatheter Valve Systems $978 35 payments
  6. AMPLATZER AMULET $803 8 payments
  7. PASCAL $638 6 payments
  8. SAPIEN 3 Ultra RESILIA $540 12 payments
  9. ANGIOVAC $426 6 payments
  10. AMPLATZER Occluders $400 1 payment
  11. Other $4,357 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $4,500 1 payment
  2. Abiomed $59 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

906

Median for Interventional Cardiology: 2,236

Drug cost

$204,753

Median for Interventional Cardiology: $380,412

Branded share of claims

33.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 88 $90,686
Xarelto Rivaroxaban Brand 57 $56,194
Entresto Sacubitril/Valsartan Brand 31 $35,641
Brilinta Ticagrelor Brand 21 $15,446
Atorvastatin Calcium Generic 113 $1,022
Metoprolol Succinate Generic 75 $940
Clopidogrel Clopidogrel Bisulfate Brand 65 $913
Potassium Chloride Generic 40 $580
Carvedilol Generic 73 $532
Bumetanide Generic 13 $466

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$180,773

Medicare's payments for the services billed

Medicare patients

1,423

Average age 76

Services billed

3,240

709 women, 714 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 54%
Atrial fibrillation 43%
Heart failure 42%
Diabetes 38%
Chronic kidney disease 37%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $9
$9 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

758 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record